X4 PHARMACEUTICALS, INC Temporary Equity, Dividends, Adjustment
X4 PHARMACEUTICALS, INC (XFOR) reported Temporary Equity, Dividends, Adjustment of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:TemporaryEquityDividendsAdjustment · last filed 2022-03-17
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for the quarter ending 2020-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for the quarter ending 2020-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for the quarter ending 2020-06-30 was $0.00.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for fiscal 2021 was $0.00.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for fiscal 2019 was $592.00K, a 80.27% decline from fiscal 2018.
- X4 PHARMACEUTICALS, INC temporary equity, dividends, adjustment for fiscal 2018 was $3.00M, a 0.00% change from fiscal 2017.
| Period end | Temporary Equity, Dividends, Adjustment 3 month | Temporary Equity, Dividends, Adjustment 6 month | Temporary Equity, Dividends, Adjustment 9 month | Temporary Equity, Dividends, Adjustment 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $592.00K 10-K · filed 2022-03-17 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $592.00K 10-Q · filed 2020-11-05 | $1.35M derived: sum of 4 quarters · filed 2021-03-19 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $592.00K 10-Q · filed 2020-08-04 | $1.35M derived: sum of 3 quarters · filed 2021-03-19 | $2.10M derived: sum of 4 quarters · filed 2021-03-19 |
| 2019-03-31 | $592.00K 10-Q · filed 2020-05-07 | $1.35M derived: sum of 2 quarters · filed 2021-03-19 | $2.10M derived: sum of 3 quarters · filed 2021-03-19 | $2.85M derived: sum of 4 quarters · filed 2021-03-19 |
| 2018-12-31 | $756.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $1.51M derived: sum of 2 quarters · filed 2021-03-19 | $2.26M derived: sum of 3 quarters · filed 2021-03-19 | $3.00M 10-K · filed 2021-03-19 |
| 2018-09-30 | $756.00K 10-Q · filed 2019-11-07 | $1.50M derived: sum of 2 quarters · filed 2019-11-07 | $2.24M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $748.00K 10-Q · filed 2019-08-07 | $1.49M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $740.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $3.00M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |